Australia's most trusted
source of pharma news
Posted 6 November 2024 AM
Johnson & Johnson will continue its Australian market stranglehold for Stelara - for a while longer at least - after the biosimilar most advanced in the PBS listing process threw on the brakes, deciding not to continue with reimbursement at this time.
Amgen has backed away from launching a biosimilar referencing Stelara in Australia. The pharma has two biosimilars of Stelara registered with the TGA, and garnered a PBAC recommendation for Wezlana for "psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis" at the March 2024 meeting.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.